Portola Pharmaceuticals (Portola Pharmaceuticals) 3-Year Book Growth Rate : 0.00% (As of Mar. 2020)

View and export this data going back to 2013. Start your Free Trial

What is Portola Pharmaceuticals 3-Year Book Growth Rate?

Portola Pharmaceuticals's Book Value per Share for the quarter that ended in Mar. 2020 was $0.92.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Competitive Comparison of Portola Pharmaceuticals's 3-Year Book Growth Rate

For the Biotechnology subindustry, Portola Pharmaceuticals's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Portola Pharmaceuticals's 3-Year Book Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Portola Pharmaceuticals's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Portola Pharmaceuticals's 3-Year Book Growth Rate falls into.

Portola Pharmaceuticals 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Portola Pharmaceuticals (NAS:PTLA) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Portola Pharmaceuticals 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Portola Pharmaceuticals's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Portola Pharmaceuticals (Portola Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Portola Pharmaceuticals Inc (NAS:PTLA) » Definitions » 3-Year Book Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

270 E. Grand Avenue, South San Francisco, CA, USA, 94080

Website

https://www.portola.com

Portola Pharmaceuticals Inc is a biotechnology company focused on developing and commercializing novel therapeutics. The company focuses on areas of thrombosis, other hematologic disorders, and inflammation for patients who have limited or no approved treatment options. Portola focuses on biomarker or genetic approaches to clinical development that it believes will increase the probability of clinical, regulatory, and commercial success of first-in-class therapies. The company also uses collaborative agreements.

Executives

Dennis M Fenton	director
John B Moriarty	officer: EVP, General Counsel	ALEXION PHARMACEUTICALS, 352 KNOTTER DRIVE, CHESHIRE CT 06410
Hollings Renton	director
David C Stump	director
Ted W Love	director	C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO CA 94080
John Johnson	director	DENDREON CORPORATION, 1301 2ND AVENUE, SEATTLE WA 98101
Jeffrey W Bird	director	755 PAGE MILL RD STE A-200, PALO ALTO CA 94304-1005
Henry Ward Wolff	director	6701 KAISER DRIVE, FREMONT CA 94555
J. Scott Garland	director, officer: President and CEO	210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Laura Brege	director	C/O ONYX PHARMACEUTICALS, INC., 2100 POWELL STREET, EMERYVILLE CA 94608
Mardi Dier	officer: EVP and CFO	C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS CA 91301
Rajiv Patni	officer: EVP, CMO	C/O OCERA THERAPEUTICS, INC., 525 UNIVERSITY AVENUE, SUITE 610, PALO ALTO CA 94301
John T Curnutte	officer: EVP R&D	PORTOLA PHARMACEUTICALS, INC., 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Charles J Homcy	other: Former Director	PORTOLA PHARMACEUTICALS, INC., 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
William Lis	director, officer: Chief Executive Officer	PORTOLA PHARMACEUTICALS, INC., 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080